Table 1.
Clinical, laboratory, and demographic data of healthy volunteers (HV) and renovascular hypertensive (RVH) patients treated with percutaneous transluminal renal angioplasty (PTRA) and either vehicle or elamipretide (ELAM).
| Parameter | HV | RVH | |
|---|---|---|---|
| PTRA+ELAM | PTRA+Placebo | ||
| Demographics: | |||
| Number of patients | 5 | 6 | 8 |
| Age (years) | 65.0±8.3 | 65.3±7.1 | 69.5±9.7 |
| Gender (Female/Male) | 3/2 | 3/3 | 4/4 |
| Body Mass IndexϮ | 31.7 (27.9–32.3) | 29.2 (25.2–38.9) | 31.5 (25.2–39.6) |
| Related laboratory measures: | |||
| Systolic blood pressure (mmHg) | 114.2±16.7 | 149.5±16.6* | 150.6±21.2* |
| Diastolic blood pressure (mmHg) | 65.0±6.1 | 82.8±6.8 | 73.0±11.4 |
| Mean blood pressure (mm Hg) | 81.4±9.1 | 105.1±7.8* | 98.9±12.3* |
| PRA (ng/ml per hour) | 0.54±0.4 | 14.5±11.6* | 10.4±6.8* |
| Concomitant medication: | |||
| No. of Antihypertensive drugsϮ | 0 | 3.5 (2–5)* | 4 (2–6)* |
| Lipid-lowering drugs (No. of patients) | 0/5 | 5/6* | 5/8* |
| Renal function: | |||
| Serum creatinine (mg/dL) | 0.9±0.2 | 1.6±0.4* | 1.8±0.5* |
| eGFR-CDK-EPI (ml/min/1.73/m2) | 78.3±9.0 | 40.7±13.4* | 36.0±10.2* |
| Urine protein (mg/24hr) | 93.0 (72.0–93.0) | 134.0 (67.5–4910.5) | 79.0 (39.5–1038.5) |
| Albumin-creatinine-ratio (mg/g) | 48.5±43.6 | 118.0±154.3 | 131.2±171.5 |
eGFR-CKD-EPI: estimated glomerular filtration rate-chronic kidney disease epidemiology collaboration.
*
p≤0.05 vs. HV.
Ϯ
Median (interquartile range) reported because of skewed data.